Cargando…
Trial watch: Prognostic and predictive value of the immune infiltrate in cancer
Solid tumors are constituted of a variety of cellular components, including bona fide malignant cells as well as endothelial, structural and immune cells. On one hand, the tumor stroma exerts major pro-tumorigenic and immunosuppressive functions, reflecting the capacity of cancer cells to shape the...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518505/ https://www.ncbi.nlm.nih.gov/pubmed/23243596 http://dx.doi.org/10.4161/onci.22009 |
_version_ | 1782252564681588736 |
---|---|
author | Senovilla, Laura Vacchelli, Erika Galon, Jerome Adjemian, Sandy Eggermont, Alexander Fridman, Wolf Hervé Sautès-Fridman, Catherine Ma, Yuting Tartour, Eric Zitvogel, Laurence Kroemer, Guido Galluzzi, Lorenzo |
author_facet | Senovilla, Laura Vacchelli, Erika Galon, Jerome Adjemian, Sandy Eggermont, Alexander Fridman, Wolf Hervé Sautès-Fridman, Catherine Ma, Yuting Tartour, Eric Zitvogel, Laurence Kroemer, Guido Galluzzi, Lorenzo |
author_sort | Senovilla, Laura |
collection | PubMed |
description | Solid tumors are constituted of a variety of cellular components, including bona fide malignant cells as well as endothelial, structural and immune cells. On one hand, the tumor stroma exerts major pro-tumorigenic and immunosuppressive functions, reflecting the capacity of cancer cells to shape the microenvironment to satisfy their own metabolic and immunological needs. On the other hand, there is a component of tumor-infiltrating leucocytes (TILs) that has been specifically recruited in the attempt to control tumor growth. Along with the recognition of the critical role played by the immune system in oncogenesis, tumor progression and response to therapy, increasing attention has been attracted by the potential prognostic and/or predictive role of the immune infiltrate in this setting. Data from large clinical studies demonstrate indeed that a robust infiltration of neoplastic lesions by specific immune cell populations, including (but not limited to) CD8(+) cytotoxic T lymphocytes, Th1 and Th17 CD4(+) T cells, natural killer cells, dendritic cells, and M1 macrophages constitutes an independent prognostic indicator in several types of cancer. Conversely, high levels of intratumoral CD4(+)CD25(+)FOXP3(+) regulatory T cells, Th2 CD4(+) T cells, myeloid-derived suppressor cells, M2 macrophages and neutrophils have frequently been associated with dismal prognosis. So far, only a few studies have addressed the true predictive potential of TILs in cancer patients, generally comforting the notion that—at least in some clinical settings—the immune infiltrate can reliably predict if a specific patient will respond to therapy or not. In this Trial Watch, we will summarize the results of clinical trials that have evaluated/are evaluating the prognostic and predictive value of the immune infiltrate in the context of solid malignancies. |
format | Online Article Text |
id | pubmed-3518505 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Landes Bioscience |
record_format | MEDLINE/PubMed |
spelling | pubmed-35185052012-12-14 Trial watch: Prognostic and predictive value of the immune infiltrate in cancer Senovilla, Laura Vacchelli, Erika Galon, Jerome Adjemian, Sandy Eggermont, Alexander Fridman, Wolf Hervé Sautès-Fridman, Catherine Ma, Yuting Tartour, Eric Zitvogel, Laurence Kroemer, Guido Galluzzi, Lorenzo Oncoimmunology Review Solid tumors are constituted of a variety of cellular components, including bona fide malignant cells as well as endothelial, structural and immune cells. On one hand, the tumor stroma exerts major pro-tumorigenic and immunosuppressive functions, reflecting the capacity of cancer cells to shape the microenvironment to satisfy their own metabolic and immunological needs. On the other hand, there is a component of tumor-infiltrating leucocytes (TILs) that has been specifically recruited in the attempt to control tumor growth. Along with the recognition of the critical role played by the immune system in oncogenesis, tumor progression and response to therapy, increasing attention has been attracted by the potential prognostic and/or predictive role of the immune infiltrate in this setting. Data from large clinical studies demonstrate indeed that a robust infiltration of neoplastic lesions by specific immune cell populations, including (but not limited to) CD8(+) cytotoxic T lymphocytes, Th1 and Th17 CD4(+) T cells, natural killer cells, dendritic cells, and M1 macrophages constitutes an independent prognostic indicator in several types of cancer. Conversely, high levels of intratumoral CD4(+)CD25(+)FOXP3(+) regulatory T cells, Th2 CD4(+) T cells, myeloid-derived suppressor cells, M2 macrophages and neutrophils have frequently been associated with dismal prognosis. So far, only a few studies have addressed the true predictive potential of TILs in cancer patients, generally comforting the notion that—at least in some clinical settings—the immune infiltrate can reliably predict if a specific patient will respond to therapy or not. In this Trial Watch, we will summarize the results of clinical trials that have evaluated/are evaluating the prognostic and predictive value of the immune infiltrate in the context of solid malignancies. Landes Bioscience 2012-11-01 /pmc/articles/PMC3518505/ /pubmed/23243596 http://dx.doi.org/10.4161/onci.22009 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited. |
spellingShingle | Review Senovilla, Laura Vacchelli, Erika Galon, Jerome Adjemian, Sandy Eggermont, Alexander Fridman, Wolf Hervé Sautès-Fridman, Catherine Ma, Yuting Tartour, Eric Zitvogel, Laurence Kroemer, Guido Galluzzi, Lorenzo Trial watch: Prognostic and predictive value of the immune infiltrate in cancer |
title | Trial watch: Prognostic and predictive value of the immune infiltrate in cancer |
title_full | Trial watch: Prognostic and predictive value of the immune infiltrate in cancer |
title_fullStr | Trial watch: Prognostic and predictive value of the immune infiltrate in cancer |
title_full_unstemmed | Trial watch: Prognostic and predictive value of the immune infiltrate in cancer |
title_short | Trial watch: Prognostic and predictive value of the immune infiltrate in cancer |
title_sort | trial watch: prognostic and predictive value of the immune infiltrate in cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518505/ https://www.ncbi.nlm.nih.gov/pubmed/23243596 http://dx.doi.org/10.4161/onci.22009 |
work_keys_str_mv | AT senovillalaura trialwatchprognosticandpredictivevalueoftheimmuneinfiltrateincancer AT vacchellierika trialwatchprognosticandpredictivevalueoftheimmuneinfiltrateincancer AT galonjerome trialwatchprognosticandpredictivevalueoftheimmuneinfiltrateincancer AT adjemiansandy trialwatchprognosticandpredictivevalueoftheimmuneinfiltrateincancer AT eggermontalexander trialwatchprognosticandpredictivevalueoftheimmuneinfiltrateincancer AT fridmanwolfherve trialwatchprognosticandpredictivevalueoftheimmuneinfiltrateincancer AT sautesfridmancatherine trialwatchprognosticandpredictivevalueoftheimmuneinfiltrateincancer AT mayuting trialwatchprognosticandpredictivevalueoftheimmuneinfiltrateincancer AT tartoureric trialwatchprognosticandpredictivevalueoftheimmuneinfiltrateincancer AT zitvogellaurence trialwatchprognosticandpredictivevalueoftheimmuneinfiltrateincancer AT kroemerguido trialwatchprognosticandpredictivevalueoftheimmuneinfiltrateincancer AT galluzzilorenzo trialwatchprognosticandpredictivevalueoftheimmuneinfiltrateincancer |